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L&Blt B&LOON ANGIOPLASTY: CORONARY ANGIOGRAPHIC 
POLGOW-UP OFA kiULTICB7l’RR T IAL 
J. Richard Smars, HD, FACC, Vincent P. Reyes, MD, H.W.T. 
Plokker , MD, PhD, James J. PerRuson, MD, Wayne E. Dear, 
HD, FACC, I. Nigel Sinclair, RR, Spencer R. King III, MD, 
FACC. Ronald D. Jenkins, MD, Robert D. Sefian, MD, 
Anthony Richards, MD, Leonard Schwartz, HD, FACC’, and the 
LRA Study Group. Eerper Hospital/Wayne State University, 
Datroit, HI. 
A multicenter trial has been initiated to determine 
whether coronary luminol diameter is increased to a 
greater degree, mutely and chronically, by percutaneous 
lamer balloon MgiOpleSty (m), compared t0 initial or 
role PTCA with a balloon of identical site (3.0 x 20 
4. Computerized frme9e analysis was perfowed on 
from 143 conrecutive patients, including those 
initial non-randomized trial (n - 64) and the 
ients in a randomhed trial (n - 61, LU with 1 
ferent NdrYAG lsrer dose levels VS. PTCA alone). 
Results: PTCA increased minimum luminal di 
~.6+0.3 nrm to 1.79.6 mm with a furth 
< 0,001)” to 2.3iO.3 am acutely after LEA (n - 143). All 
patients in whom Dab < 1.5 mm after PTCA (mean - 
in-> 1.5 mm after LBA (mean - 
reams in Dmin were found for 
dose levels ( p > 0. OS). Hem Dmin was 
unchanged at 2.3s.4 m and 2.220.7 ma 1 day (n m 51) and 
36) post LBA, respectively. Three months 
Dmin decreased to 1.7tO.6 mm (n = 20) 
with no further chatqe at 6 amnths (mean = 1.63.4 om, n 
= 11). Maximum diameter w8s unchanged from pre-PICA 
values (3.w.3 um) at 811 time inter&. Conclusion: 
LM is more effective than PTCA acutely and subacutely. 
Longer term results 
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catheter tip mergy density of 35- 
&nt vemel diss 
corcmry disease patients. 
Schechtm&, Ph.D., 
@fore hoepital dia 
trial proarrhythmi 
roarrbythmia (WA, 
were discharged on 
loat to follow up. 
uninterrupted in 69P (65%) over a period of 864t542 
6, At 1, 2, and 9 y., 64X, 59X, and 59% of P 
eapectively, remain on Rx. One 8 
fter ceraatlon of Rx. We conclud 
elected P with SVTA, Rx with F wa 
hia long-term aucceaa rate, and II 
obaerved, however, ueually during 
Thue, if ueed for these inditatione, P should be started 
in the hoepltal and the prtlent observed until the 
effect8 of steady-state Rx have been fully amuained. 
